Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX studyDaratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study, Published online: 01 May 2018; doi:10.1038/s41408-018-0071-xDaratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study

Source: Blood Cancer Journal - May 1, 2018 Category: Hematology Authors: Kenshi Suzuki Meletios A. Dimopoulos Naoki Takezako Shinichiro Okamoto Atsushi Shinagawa Morio Matsumoto Hiroshi Kosugi Sung-Soo Yoon Shang-Yi Huang Xiang Qin Ming Qi Shinsuke Iida Source Type: research